Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
8.00
-1.23 (-13.33%)
At close: Sep 25, 2025, 3:59 PM
7.83
-2.17%
After-hours: Sep 25, 2025, 05:25 PM EDT
-13.33% (1D)
| Bid | 7.91 |
| Market Cap | 290.42M |
| Revenue (ttm) | 726.33K |
| Net Income (ttm) | -62.13M |
| EPS (ttm) | -1.9 |
| PE Ratio (ttm) | -4.21 |
| Forward PE | -5.24 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.03 |
| Volume | 20,458,674 |
| Avg. Volume (20D) | 1,000,809 |
| Open | 9.60 |
| Previous Close | 9.23 |
| Day's Range | 7.25 - 9.60 |
| 52-Week Range | 1.10 - 10.08 |
| Beta | 0.43 |
| Ex-Dividend Date | n/a |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 hours ago
Immuneering shares are trading lower after the com...
Unlock content with
Pro Subscription
1 day ago
+7.45%
Immuneering shares are trading higher after the company reported 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib plus mGnP.
